ConductScience.org, home

Trial · NCT03242018

Results by group37

Each measurement the trial posted, group by group, in the words and numbers it posted.

OutcomeGroupCategoryValueSpreadUnits
Change From Baseline in HbA1c at Week 26 Comparing Sotagliflozin 400 mg Versus PlaceboPlacebo-0.11Standard Error 0.151percentage of HbA1c
Change From Baseline in HbA1c at Week 26 Comparing Sotagliflozin 400 mg Versus PlaceboSotagliflozin 400 mg-0.40Standard Error 0.131percentage of HbA1c
Change From Baseline in HbA1c at Week 26 Comparing Sotagliflozin 200 mg Versus PlaceboPlacebo-0.11Standard Error 0.151percentage of HbA1c
Change From Baseline in HbA1c at Week 26 Comparing Sotagliflozin 200 mg Versus PlaceboSotagliflozin 200 mg-0.07Standard Error 0.162percentage of HbA1c
Change From Baseline in Fasting Plasma Glucose (FPG) at Week 26Placebo0.069Standard Error 0.4482millimole per liter (mmol/L)
Change From Baseline in Fasting Plasma Glucose (FPG) at Week 26Sotagliflozin 200 mg-0.291Standard Error 0.5056millimole per liter (mmol/L)
Change From Baseline in Fasting Plasma Glucose (FPG) at Week 26Sotagliflozin 400 mg-0.644Standard Error 0.4348millimole per liter (mmol/L)
Change From Baseline in Body Weight at Week 26Placebo0.39Standard Error 0.615kilogram (kg)
Change From Baseline in Body Weight at Week 26Sotagliflozin 200 mg-0.43Standard Error 0.480kilogram (kg)
Change From Baseline in Body Weight at Week 26Sotagliflozin 400 mg-1.02Standard Error 0.490kilogram (kg)
Change From Baseline in SBP at Week 12 in Participants With Baseline SBP ≥130 mmHgPlacebo-2.70Standard Error 1.815mmHg
Change From Baseline in SBP at Week 12 in Participants With Baseline SBP ≥130 mmHgSotagliflozin 200 mg-4.84Standard Error 1.882mmHg
Change From Baseline in SBP at Week 12 in Participants With Baseline SBP ≥130 mmHgSotagliflozin 400 mg-7.10Standard Error 1.842mmHg
Change From Baseline in SBP at Week 12 for All ParticipantsPlacebo-2.50Standard Error 1.762mmHg
Change From Baseline in SBP at Week 12 for All ParticipantsSotagliflozin 200 mg-5.74Standard Error 1.752mmHg
Change From Baseline in SBP at Week 12 for All ParticipantsSotagliflozin 400 mg-7.86Standard Error 1.794mmHg
Percentage Change From Baseline in the Urine Albumin: Creatinine Ratio (UACR) at Week 26 in Participants With Baseline UACR >30 Milligrams Per Gram (mg/g)Placebo-4.56Standard Error NApercent change
Percentage Change From Baseline in the Urine Albumin: Creatinine Ratio (UACR) at Week 26 in Participants With Baseline UACR >30 Milligrams Per Gram (mg/g)Sotagliflozin 200 mg-26.99Standard Error NApercent change
Percentage Change From Baseline in the Urine Albumin: Creatinine Ratio (UACR) at Week 26 in Participants With Baseline UACR >30 Milligrams Per Gram (mg/g)Sotagliflozin 400 mg-30.66Standard Error NApercent change
Percentage of Participants With HbA1c <6.5% at Week 26Placebo2.2percentage of participants

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT03242018/results